Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.verified

REGN

Price:

$1155.38

Market Cap:

$125.26B

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carci...[Read more]

Industry

Biotechnology

IPO Date

1991-04-02

Stock Exchange

NASDAQ

Ticker

REGN

The Current Ratio as of September 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 5.44

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.44. This represents a change of 0.82% compared to the average of 5.39 of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical Current Ratio (quarterly & annually)

How has REGN Current Ratio performed in the past?

The mean historical Current Ratio of Regeneron Pharmaceuticals, Inc. over the last ten years is 5.20. The current 5.44 Current Ratio has changed 10.37% with respect to the historical average. Over the past ten years (40 quarters), REGN's Current Ratio was at its highest in in the June 2018 quarter at 6.48. The Current Ratio was at its lowest in in the June 2020 quarter at 2.12.

Quarterly (TTM)
Annual

Average

5.20

Median

5.71

Minimum

3.99

Maximum

5.95

Regeneron Pharmaceuticals, Inc. (REGN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 44.95%

Maximum Annual Current Ratio = 5.95

Minimum Annual Increase = -52.93%

Minimum Annual Current Ratio = 3.99

Quarterly (TTM)
Annual
YearCurrent RatioChange
20235.69-0.74%
20225.73-3.60%
20215.9530.86%
20204.54-22.93%
20195.900.15%
20185.891.76%
20175.7944.95%
20163.99-10.29%
20154.4510.05%
20144.04-52.93%

Regeneron Pharmaceuticals, Inc. (REGN) Average Current Ratio

How has REGN Current Ratio performed in the past?

The current Current Ratio of Regeneron Pharmaceuticals, Inc. (REGN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

5.79

5-year avg

5.56

10-year avg

5.20

Regeneron Pharmaceuticals, Inc. (REGN) Current Ratio vs. Peers

How is REGN’s Current Ratio compared to its peers?

Regeneron Pharmaceuticals, Inc.’s Current Ratio is less than CRISPR Therapeutics AG (15.73), greater than Novo Nordisk A/S (0.94), greater than Sarepta Therapeutics, Inc. (3.90), less than Intellia Therapeutics, Inc. (7.21), greater than Incyte Corporation (1.92), greater than Alnylam Pharmaceuticals, Inc. (3.01), greater than United Therapeutics Corporation (4.35), greater than Ultragenyx Pharmaceutical Inc. (3.54), greater than Apellis Pharmaceuticals, Inc. (5.08), greater than PTC Therapeutics, Inc. (2.23), greater than Reata Pharmaceuticals, Inc. (3.21), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Krystal Biotech, Inc. (9.50), less than Madrigal Pharmaceuticals, Inc. (8.72), greater than BeiGene, Ltd. (1.98), greater than BioMarin Pharmaceutical Inc. (3.05), less than ImmunoGen, Inc. (5.47), less than Prometheus Biosciences, Inc. (37.56), greater than Arrowhead Pharmaceuticals, Inc. (4.65), less than Ionis Pharmaceuticals, Inc. (7.61),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Regeneron Pharmaceuticals, Inc.'s Current Ratio?

How is the Current Ratio calculated for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the highest Current Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 3-year average Current Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 5-year average Current Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

How does the current Current Ratio for Regeneron Pharmaceuticals, Inc. (REGN) compare to its historical average?